Europe Bioprocess Technology Market Forecast to 2028 - Regional Analysis By Type, Modality, and End User

The Europe bioprocess technology market is expected to grow from US$ 12,290.88 million in 2023 to US$ 26,588.36 million by 2028. It is estimated to grow at a CAGR of 16.7% from 2023 to 2028.

Introducing Advanced Bioprocess Technologies Drives Europe Bioprocess Technology Market

Advanced bioprocess technologies bridge R&D with production. Several players are introducing a wide range of new bioprocessing technologies in the market. On December 4, 2020, IDBS (a provider of software informatics solutions for the biotech and pharmaceutical industries) announced the launch of Polar. Polar creates a new product category called BioPharma Lifecycle Management (BPLM) to streamline drug development and production in biopharma research. Polar is designed and deployed to rapidly solve challenges associated with workflow, process quality, collaboration, and data analysis that have plagued the existing software solutions, including laboratory information management system (LIMS) and electronic laboratory notebook (ELN). As a result, there will be less human errors and an improvement in overall accuracy. It will reduce manual data processing and transcription, leading to fewer human errors and enhanced overall accuracy. It also has extensive search features that make it easier for users to locate what they are searching for, preventing the need for pointless duplication of effort.

METTLER TOLEDO’s Dynochem Biologics is a purpose-built simulation software that supports upstream and downstream unit activities in bioprocessing at any scale. Bioprocess engineers and scientists use the software to choose appropriate process operating parameters and establish scales equivalency. Utilities enable quick evaluation of equipment performance with minimal data, whereas more potent models leverage the existing data streams for process characterization. Initial projects can be completed quickly with the help of responsive application expertise, rich training resources, and a model library that is already built. Peptides, mAbs, vaccinations, and viral vectors are a few examples of the many applications.

Merck’s new BioContinuum Platform advances biotherapeutic drug manufacturing through improved efficiency, simplified plant operations, and greater quality and consistency. In addition, Merck’s Pellicon Single-Pass Tangential Flow Filtration aid in intensifying operations associated with the purification of therapeutic proteins. Thus, the introduction of various new-age bioprocess technologies is likely to provide lucrative opportunities for the market growth during the forecast period.

Europe Bioprocess Technology Market Overview

According to Germany Trade & Invest, the country is the second largest exporter of medicinal products and ranks among the top pharmaceutical producers across the world. Owing to the rising demand for personalized medicine, Germany has also evolved into one of the main suppliers of novel biopharmaceuticals. Biologics hold a considerable share of the pharmaceutical market in Germany due to their high therapeutic potential. According to a report by Germany Trade & Invest (GTAI) from 2015 to 2019, the biologics market grew by 11.6 % on average annually (more than twice the growth of the overall pharma market). The total revenue of biopharmaceuticals in Germany was US$ 13.96 billion in 2019, equivalent to more than a quarter of the pharmaceutical market. Germany has a major European pharmaceutical market and is the fourth largest across the world. In 2019, sales in the pharmaceutical industry in Germany increased by 5.7 %, from 2018, reaching US$ 51.01 billion (ex-manufacturer prices). More than 500 pharmaceutical companies are located in Germany. SMEs are the backbone of the economic sector, with around 90% of drug manufacturers having less than 500 employees. Thus, the growing pharmaceutical market in Europe will propel the use of bioprocess technology as biotechnology helps the pharmaceutical companies develop new products, processes, methods, and services and improve existing ones.
Europe Bioprocess Technology Market Revenue and Forecast to 2028 (US$ Million)

Europe Bioprocess Technology Market Segmentation

The Europe bioprocess technology market is segmented into type, modality, end user, and country.

Based on type, the Europe bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, and consumables & accessories, and others. In 2023, the consumables & accessories segment registered the largest share in the Europe bioprocess technology market.

Based on modality, the Europe bioprocess technology market is bifurcated into single use and multiple use. In 2023, the single use segment registered a larger share in the Europe bioprocess technology market.

Based on end user, the Europe bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. In 2023, the biopharmaceutical companies segment registered the largest share in the Europe bioprocess technology market.

Based on country, the Europe bioprocess technology market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2023, Germany segment registered a largest share in the Europe bioprocess technology market.

BioPharma Dynamics Ltd; Corning Inc; Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; STAMM Biotech; and Thermo Fisher Scientific Inc are the leading companies operating in the Europe bioprocess technology market.

Reasons to Buy

• Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe bioprocess technology market.
• Highlights key business priorities in order to assist companies to realign their business strategies
• The key findings and recommendations highlight crucial progressive industry trends in the Europe bioprocess technology market, thereby allowing players across the value chain to develop effective long-term strategies
• Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
• Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the bioprocess technology market, as well as those hindering it
• Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution